company background image
HAMLET B logo

Hamlet BioPharma NGM:HAMLET B Stock Report

Last Price

kr1.73

Market Cap

kr290.2m

7D

-12.2%

1Y

-51.5%

Updated

26 Mar, 2024

Data

Company Financials

Hamlet BioPharma AB (publ)

NGM:HAMLET B Stock Report

Market Cap: kr290.2m

HAMLET B Stock Overview

Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden.

HAMLET B fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Hamlet BioPharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hamlet BioPharma
Historical stock prices
Current Share Pricekr1.73
52 Week Highkr3.92
52 Week Lowkr1.00
Beta0.93
1 Month Change-8.22%
3 Month Change28.15%
1 Year Change-51.47%
3 Year Change-77.91%
5 Year Change-65.40%
Change since IPO-25.86%

Recent News & Updates

Recent updates

Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Jul 04
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

Mar 04
Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

Nov 10
We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Jun 17
We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Oct 12
Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

Mar 17
Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

Shareholder Returns

HAMLET BSE BiotechsSE Market
7D-12.2%0.2%2.0%
1Y-51.5%4.8%17.8%

Return vs Industry: HAMLET B underperformed the Swedish Biotechs industry which returned 4.8% over the past year.

Return vs Market: HAMLET B underperformed the Swedish Market which returned 17.8% over the past year.

Price Volatility

Is HAMLET B's price volatile compared to industry and market?
HAMLET B volatility
HAMLET B Average Weekly Movement13.1%
Biotechs Industry Average Movement8.5%
Market Average Movement6.1%
10% most volatile stocks in SE Market13.1%
10% least volatile stocks in SE Market3.4%

Stable Share Price: HAMLET B's share price has been volatile over the past 3 months.

Volatility Over Time: HAMLET B's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
19997Petter Lindqvisthttps://www.hamletpharma.com

Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer.

Hamlet BioPharma AB (publ) Fundamentals Summary

How do Hamlet BioPharma's earnings and revenue compare to its market cap?
HAMLET B fundamental statistics
Market capkr290.23m
Earnings (TTM)-kr26.59m
Revenue (TTM)kr2.38m

122.1x

P/S Ratio

-10.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HAMLET B income statement (TTM)
Revenuekr2.38m
Cost of Revenuekr0
Gross Profitkr2.38m
Other Expenseskr28.97m
Earnings-kr26.59m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 24, 2024

Earnings per share (EPS)-0.16
Gross Margin100.00%
Net Profit Margin-1,118.81%
Debt/Equity Ratio0%

How did HAMLET B perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.